AEZS:NSD-Aeterna Zentaris Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.83

Change

-0.05 (-5.96)%

Market Cap

USD 0.11B

Volume

2.58M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-2.81 (-1.84%)

USD61.31B 102.33 81.58
VRTX Vertex Pharmaceuticals Incorpo..

+1.67 (+0.79%)

USD55.06B 20.27 14.23
REGN Regeneron Pharmaceuticals, Inc

+10.03 (+1.98%)

USD54.03B 14.44 11.17
BNTX BioNTech SE

-5.34 (-2.87%)

USD47.83B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.34 (+0.78%)

USD38.01B 55.82 39.93
BGNE BeiGene, Ltd

-3.87 (-1.24%)

USD27.16B N/A N/A
SGEN Seagen Inc

-0.06 (-0.04%)

USD26.27B 40.39 34.48
RPRX Royalty Pharma plc

-0.40 (-0.99%)

USD24.64B 22.60 15.13
GMAB Genmab A/S

+0.37 (+1.02%)

USD24.15B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AEZS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 95.44% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.44% 96% A 96% A
Trailing 12 Months  
Capital Gain -14.14% 39% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.14% 39% F 12% F
Trailing 5 Years  
Capital Gain -75.03% 23% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.03% 23% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -9.42% 22% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.42% 22% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 72.93% 42% F 23% F
Risk Adjusted Return -12.91% 25% F 17% F
Market Capitalization 0.11B 20% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.80 39% F 59% F
Price/Book Ratio 1.71 87% B+ 70% C-
Price / Cash Flow Ratio -25.87 84% B 87% B+
EV/EBITDA 0.14 73% C 95% A
Management Effectiveness  
Return on Equity -22.30% 82% B- 35% F
Return on Invested Capital -120.19% 12% F 6% F
Return on Assets -6.77% 88% B+ 32% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.52 78% C+ 67% D+
Short Percent 4.43% 67% D+ 44% F
Beta 2.34 10% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.